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Background: Chronic hepatitis B (CHB) can progress to cirrhosis, hepatocellular carcinoma (HCC) and ultimately
liver-related death. Although oral antiviral therapy for patients with CHB reduces the risk of such complications,
once cirrhosis is established, the benefits of antiviral therapy are not robustly demonstrated. According to traditional
Chinese medicine (TCM), some Chinese herbal medicines promote blood circulation and soften hard masses, and
therefore they may block and reverse hepatic fibrosis. The aim of this study is to evaluate the effects of TCM tablets
of the compound biejia ruangan (RGT) administered for fibrosis, and entecavir (ETV), on the development of HCC in
patients with CHB or hepatitis B virus (HBV)-related compensated cirrhosis.
Methods/design: This multicenter, centrally randomized, double-blind, placebo-controlled, parallel-group study is
planned to complete within 5 years. For the study, 1,000 with CHB or HBV-related compensated cirrhosis are randomly
assigned in a 1:1 ratio to a treatment group (0.5 mg ETV once daily; 2 g RGT three times daily) or a control group
(0.5 mg ETV once daily; 2 g RGT dummy agent three times daily). The primary end points are the development of HCC
and liver-related death. Secondary end points include disease progression and overall survival.
Discussion: Although antiviral therapy can achieve sustained suppression of HBV replication, thereby preventing cirrhosis,
patients with CHB treated with nucleos(t)ide analogs (NUCs) retain a higher risk for HCC compared with patients with
inactive disease. Although previous clinical trials with RGT have confirmed the efficacy of blocking and reversing hepatic
fibrosis in patients with CHB or compensated cirrhosis, the long-term risk for HCC or disease progression in these patients
treated with combination of RGT and NUCs compared with NUCs alone is unclear. Therefore, it is necessary to investigate
the effects of the RGT blockade and reversal of hepatic fibrosis on the development of HCC in patients with CHB or
HBV-related compensated cirrhosis in large, prospective, multicenter, double-blind, randomized, controlled trials in China.
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Latin name English name
Biejia Carapax trionycis Turtle shell
Ezhu Rhizoma curcumae Zedoray rhizome
Chishao Radix Paeoniae rubra Peony root
Danggui Radix Angelica sinensis Angelica sinensis
Sanqi Radix notoginseng Pseudo-ginseng
Dangshen Radix codonopsis Campanumaea pilosula
Huangqi Radix astragali Astragalus
Ziheche Placenta hominis Dried human placenta
Dongchongxiacao Cordyceps sinensis Plant worms
Banlangen Radix isatidis Baphicacanthus root
Lianqiao Fructus forsythiae Farsythio
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Hepatitis B virus (HBV) infection is a major health prob-
lem worldwide with an estimated 350 million chronic
carriers [1], and carriers in China account for 33% of all
chronic carriers globally [2,3]. Although treatment of
chronic hepatitis B (CHB) has dramatically improved
over the past decade, chronic HBV infection is still the
most common underlying cause of hepatocellular carcin-
oma (HCC), which remains one of the most common
cancers worldwide. A large longitudinal epidemiological
study of the natural history of patients with chronic
HBV infection has shown that baseline HBV DNA level
or cirrhosis is an independent predictor for the develop-
ment of HCC [4].
Although antiviral therapy can theoretically prevent
HCC by inhibiting HBV replication and preventing the
development of, or even reversing, cirrhosis, in patients
with fibrosis or cirrhosis, eradication or suppression of
HBV does not remove this risk and occurrence of HCC,
but can control the complications and gain time to pre-
pare for liver transplantation [5-7]. Antiviral therapy has
minimal side effects and sustained suppression of HBV
replication can be achieved, thus preventing such compli-
cations. However, patients with CHB treated with nucleos
(t)ide analogs (NUCs) retain a higher risk for HCC com-
pared with patients with inactive stage disease [8].
According to traditional Chinese medicine (TCM),
Chinese medicines promoting blood circulation and soft-
ening hard masses may be appropriate for blocking and
reversing hepatic fibrosis in CHB or CHB-related com-
pensated cirrhosis. Over the past decade, the role of
TCM in the treatment and prevention of fibrosis has
been confirmed by a growing number of experiments
and clinical studies [9]. To date, no randomized clinical
trial (RCT) has reported whether TCM (tablets of the
compound biejia ruangan; RGT) administered to block
and reverse hepatic fibrosis in CHB or HBV-related
compensated cirrhosis decreases the risk of developing
HCC. RGT (Inner Mongolia Furui Medical Science Co
Ltd, Wulanchabu, China) was the first antifibrotic herb
approved by the Chinese Food and Drug Administration
(CFDA) for fibrotic liver disease in China. The main
components of RGT are: turtle shell, zedoray rhizome,
peony root, Angelica sinensis, pseudo-ginseng, campanu-
maea pilosula, Astragalus, dried human placenta, plant
worms, Baphicacanthus root and farsythio (Table 1).
RGT can soften hardness to dissipate stagnation, and
disperse blood stasis and detoxification, and enhance qi
(biological substances or activities that preserve life)
and blood. Syndromes in Chinese medicine include: (1)
weakening of both qi and blood, (2) blockage of merid-
ians (circulation channels for qi) by blood stasis and (3)
generation of dampness and heat (inflammatory patho-
gens). All composites in this prescription are commonlyused clinically for chronic liver disease, to soften hard
masses and dissolve stagnation, and at the same time, to
secure essence and eliminate evil. The quality of the
herbal drugs was controlled as follows. First, as a specific
treatment of liver fibrosis and early cirrhosis, RGT was
approved by the CFDA in 1999, with the license number
Z1999101. Second, all the components of RGT are pur-
chased from designated and certificated herb plantations.
None of these herb providers has changed during the
past 10 years. Third, the production workshops for RGT
are also certified by the Good Manufacturing Practices
standard. No serious adverse effects have been reported
even though the drug entered the market >15 years ago.
Finally, RGT has passed the Good Clinical Practice
(GCP) certification by the CFDA, which is the inter-
nationally recognized standard for the design, conduct,
recording and reporting of clinical trials involving hu-
man subjects.
Some clinical trials have demonstrated that RGT can
block the development of hepatic fibrosis and reverse
early cirrhosis [10]. Other studies have shown that RGT
can significantly improve compensated cirrhosis, espe-
cially in CHB and early cirrhosis, with a total rate of ef-
fectiveness of 81.67%; after a 1-year follow-up, the total
rate of efficacy was shown to be 76.85% [11]. Yang et al.
[12-14] have reported that RGT significantly blocks
early liver fibrosis, inhibiting the proliferation of
hepatic stellate cells, reducing collagen synthesis and
excess deposition in the space of Disse, dissolving and
absorbing formed collagen fibers, and inhibiting ex-
pression of collagen α2 (I) mRNA. It has also been
shown that RGT increases the phagocytic function of
macrophages in the abdominal cavity of mice. Zhao et al.
[15] have reported similar results, and have proposed that
RGT has antifibrotic efficacy through interaction with
multiple targets that affect hepatic fibrosis. Some studies
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compensated cirrhosis [16,17], especially HBV-related
hepatic fibrosis [18].
Although some studies have concluded that RGT can
block and reverse hepatic fibrosis in CHB, there are lim-
ited data on preventing or delaying the development of
HCC in the treatment of CHB or HBV-related compen-
sated cirrhosis. To address this issue, we are conducting
a large, prospective, multicenter, centrally randomized,
double-blind, controlled trial to establish whether RGT
can prevent or delay the development of HCC by block-
ing and reversing hepatic fibrosis in CHB or HBV-
related compensated cirrhosis. The aims of this clinical
trial are: (1) to evaluate the effect of combined applica-
tion of RGT and entecavir (ETV) on development of
HCC in patients with CHB or HBV-related compensated
cirrhosis and (2) to evaluate the efficacy of combined ap-
plication of RGT and ETV in preventing or delaying the
incidence of decompensated cirrhosis and disease pro-




This large, prospective, multicenter, centrally random-
ized, double-blind, placebo-controlled trial is being con-
ducted in nine institutions between November 2013 and
November 2018. The study meets the requirements of
the Declaration of Helsinki, and has been approved by
the ethics committees of each participating institution.
All patients with CHB or HBV-related compensated cir-
rhosis are carefully screened by a multidisciplinary team
to select suitable candidates for this clinical trial, accord-
ing to the inclusion and exclusion criteria of the present
RCT and the patients’ willingness to participate in the
study. For the study, 1,000 patients are being randomly
assigned in a 1:1 ratio to one of two groups: a treatment
group (0.5 mg ETV once daily; 2 g RGT three times
daily) or a control group [0.5 mg ETV once daily; 2 g
RGT dummy agent (similar in taste, shape and color to
RGT; main ingredients include pearl barley and grilled
germinate barley) three times daily]. During the double-
blind phase, unblinding will take place as soon as suffi-
cient evidence indicates: (1) that the effect of RGT plus
ETV blocking and reversing hepatic fibrosis (measured
by METAVIR system) is statistically superior to that with
ETV alone, (2) that RGT plus ETV does not provide a
significant advantage over ETV alone by the second liver
biopsy at week 72 of double-blind treatment or (3) safety
concerns. Patients who reach an end point are offered
open-label RGT plus ETV or ETV alone for 1 year,
and patients who have blockade and reversal of hep-
atic fibrosis are followed up after treatment and have
the option to receive RGT plus ETV as an open-labeltreatment in the event of hepatic fibrosis or necroin-
flammatory progression. However, patients with stable
or reversed disease will continue to receive antiviral
therapy with ETV alone, but those with disease pro-
gression will receive open-label RGT plus ETV as in
the control group. The study will be terminated as
soon as sufficient evidence indicates that the outcome
of patients with CHB or HBV-related compensated
cirrhosis by RGT plus ETV blockade and reversal of
hepatic fibrosis is statistically superior to that with
ETV alone or does not provide a significant advantage
over ETV. If the trial is terminated according to the
predefined criteria, patients will be offered open-label
treatment for 1 year. Liver biopsies are performed at three
defined time points: before the start of randomization
(pretreatment), at week 72 of the double-blind treatment,
and at month 24 of the open-label treatment in the
follow-up study. After 24 weeks of treatment, any patients
with a reduction in HBV DNA level from baseline <1 log
IU or 2 log copies/mL will be treated with a combination
of ETV and adefovir dipivoxil (10 mg once daily) against
HBV. The flow chart of the study is shown in Figure 1.
This study is being conducted in accordance with
the ethical principles of the Declaration of Helsinki
and is consistent with GCP guidelines and applicable
local regulatory requirements. Written informed con-
sent is obtained from all randomly assigned patients.
The primary end points in this study are the occurrence
of HCC or liver-related mortality. HCC is diagnosed either
histologically or clinically based on guidelines proposed by
the Chinese Liver Cancer Study Group [19]. According to
these criteria, patients are considered positive for HCC if
they have one or more risk factors (hepatitis B or C virus
infection, or cirrhosis) and one of the following: (1) serum
α-fetoprotein (AFP) >400 ng/mL and a positive finding on
at least one of three typical imaging studies [dynamic
computed tomography (CT), dynamic magnetic resonance
imaging (MRI) or hepatic angiography] or (2) serum AFP
<400 ng/mL and positive findings on at least two of the
three imaging studies. A positive finding for typical HCC
on dynamic CT or MRI is defined as increased arterial en-
hancement followed by decreased enhancement compared
with the liver (washout) in the portal or equilibrium phase.
Liver-related mortality is defined as death caused by hep-
atic decompensation (regardless of etiology) or HCC.
Secondary end points are disease progression and over-
all survival rate. Disease progression is defined as either
histological progression reflected by an increase in META-
VIR score of at least 1 point or clinical progression
reflected by the occurrence of decompensated cirrhosis.
Decompensated cirrhosis is defined by the development
of complications of portal hypertension (ascites, variceal
hemorrhage, hepatic encephalopathy or spontaneous bac-
terial peritonitis) and/or liver insufficiency (jaundice).
Figure 1 Flow chart of the current trial. ETV, entecavir; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; HCC, hepatocellular
carcinoma; RGT, tablet of compound biejia ruangan; TCM, traditional Chinese medicine.
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lected at three defined time points: before the start of
randomization (unless a biopsy has been performed within
3 months of randomization), at week 72 of the double-
blind treatment and at month 24 of the open-label treat-
ment during follow-up. Every patient with liver biopsy of
at least six portal tracts is included in the study. To ensure
the quality of liver tissue specimens for pathological as-
sessment, liver biopsies in all centers is performed using
unified 16G liver biopsy needles and a modified Jamshidi
Menghini needle (Allegiance Corporation, McGaw Park,
IL, USA), and the tissue is fixed in formalin and embedded
in paraffin. Two independent third-party pathologists who
are unaware of the patients’ treatment assignment, biopsy
sequence and clinical outcome will examine all biopsy
slides.
Hepatic fibrosis is assessed by the METAVIR system
for fibrosis stage and necroinflammatory activity as a
hard index [22,23]. The fibrosis stages are: no fibrosis
(F0), mild fibrosis (F1), moderate fibrosis (F2), severe fi-
brosis (F3) and cirrhosis (F4). Necroinflammatory activ-
ity is: no activity (A0) mild activity (A1), moderate
activity (A2) and severe activity (A3). Serum fibrosis bio-
markers including Fibrotest, aspartate aminotransferase
to the platelet ratio index (APRI), liver stiffness spleen
diameter to platelet ratio score (LSPS), and FibroMeters
and FibroScan are used to assess hepatic fibrosis as a
surrogate index [24,25]. Hard and surrogates indexes are
evaluated at all three time points (baseline, week 72 and
week 96 after the open label) for each patient. Changes
in liver fibrosis from baseline to weeks 72 and weeks 96
after the open label are analyzed on available pooled datausing the METAVIR scoring system and the surrogate
index.
The contraindications of liver biopsy include coagu-
lopathy, uncooperative patients, impaired mental sta-
tus, infection of the hepatic bed and extrahepatic
biliary obstruction. In addition, patients undergoing a
liver biopsy are required to have an international nor-
malized ratio <1.6 and platelet count >60 × 109/L. For
analysis of the histological end point, patients who can
be evaluated must have adequate baseline biopsy spec-
imens with a METAVIR necroinflammatory or fibrosis
score of at least 1. Progression of hepatic fibrosis or
necroinflammatory progression is defined as an in-
crease of at least 1 point.
Follow-up
At baseline, all patients are screened to confirm the
absence of HCC using abdominal ultrasonography and
laboratory analyses, including AFP level. During the
follow-up, all patients are seen at 3- to 6-month inter-
vals. Periodic surveillance is also performed with abdom-
inal ultrasonography and laboratory analyses, including
AFP level, every 3 or 6 months to screen for HCC and
other complications related to portal hypertension.
Patients also undergo endoscopy every 1 or 2 years for
screening and follow-up of gastroesophageal varices.
HBV DNA, hepatitis B surface antigen (HBsAg), anti-
HBs, hepatitis B e antigen, anti-HBe, and routine
hematological and biochemical tests are performed.
Adverse events that have occurred since the previous
visit are recorded, and toxicity is graded according to
predefined criteria.
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Inclusion criteria are as follows: (1) men or women aged
18 to 65 years; (2) persistent serum HBsAg for ≥6
months; (3) serum HBV DNA ≥2000 IU/mL or ≥10,000
copies/mL; (4) baseline liver fibrosis (liver biopsy) stage
F ≥2 (METAVIR system); (5) TCM syndrome type: blood
stasis, or blood deficiency with toxic heat retention and
(6) no antiviral or antifibrotic therapy for 6 months. Pa-
tients are excluded if they have any of the following at
enrollment: (1) history of concurrent malignancy, in-
cluding HCC; (2) baseline liver fibrosis (liver biopsy)
stage F <2 (METAVIR system); (3) immunosuppression
(organ transplantation or immunosuppressant use); (4)
severe alcoholism; (5) serious uncontrollable heart, kid-
ney, lung, endocrine, blood, metabolic or gastrointestinal
primary disease, or mental illness; (6) pregnancy or lac-
tation; (7) allergic constitution or allergic to TCM use;
(8) no prescribed medication, poor compliance, incom-
plete data affecting the efficacy and safety of those judg-
ments; (9) unsuitable for this trial according to the
researchers or (10) co-infection with hepatitis C or D
virus or HIV.
Recruitment
Nine first-class hospitals across the Eastern, Western,
Southern, Northern and Central areas of China are in-
volved in this clinical trial. Participants are recruited via
posters at each participating center.
Randomization
This study has two arms. Once enrolled, participants
who meet the inclusion criteria are informed about the
study and treatment plan. Written informed consent is
obtained when the patient accepts this plan and is will-
ing to participate. A consecutively numbered envelope is
unsealed by a research assistant. The sealed numbers are
generated by a computerized random number generator
with SAS software by Boao Tong Medical Technology
Co Ltd (Beijing, China) and are concealed and dissemi-
nated using opaque envelopes. Based on this number,
the patient is randomly assigned in a 1:1 ratio to the
treatment group (ETV + RGT, n = 500) or control group
(ETV + RGT-dummy agent, n = 500).
Sample size
We assumed that the rate of hepatic fibrosis reversal
would be 39% in the ETV-treated patients at the end of
2 years [26,27], and 61% in the RGT-treated patients.
Using PASS 2002 statistical software (NCSS, Kaysville,
UT, USA), we calculated that we need two groups of 186
cases, and each group needs to enroll 223 cases if there
is a drop-out rate of 15%, that is, a total of 446 cases.
Currently, up to 45% of all enrolled patients will be ac-
cepted for a second liver biopsy. A total of 500 cases isrequired in each group to achieve a power of 0.80 and a
significance level of 0.05 in assessing the difference be-
tween the two groups.
Safety
All adverse events, regardless of their possible associ-
ation with the disease or study treatment, are recorded.
Adverse events are considered to be serious if the inves-
tigator determines that they jeopardize the patient, are
life-threatening, or could result in hospitalization, dis-
ability or death.
Data and safety monitoring board
To promote consistent study execution at each partici-
pating center, independent monitoring visits are per-
formed to supervise trial progress, ensuring that it is
conducted, recorded and reported in accordance with
the protocol, standard operating procedures, GCP and
the applicable regulatory requirements.
The Data and Safety Monitoring Board consists of
three independent hepatologists who are not members
of the end-point committee and an independent statisti-
cian. The board protects the ethical interests and safety
of the patients by reviewing interim analyses. The board
is empowered to recommend termination of the study
on the basis of safety concerns or as soon as sufficient
evidence indicates that RGT plus ETV is statistically su-
perior to ETV alone, or that RGT plus ETV does not
provide a significant advantage over ETV alone.
Ethics
The study protocol, written informed consent and
posters were approved by the 302nd Military Hospital
Ethics Review Committee (2013145D), and were ac-
cepted by the ethics committees at each of the institu-
tions involved, and have been performed according to
the Declaration of Helsinki.
The names of all ethical bodies in the various centers
involved are the 302nd Military Hospital Ethics Review
Committee, Fuyang No 2 People’s Hospital Ethics Re-
view Committee, 88th Hospital of PLA Ethics Review
Committee, First Affiliated Hospital of Zhengzhou Uni-
versity Ethics Review Committee, Fuzhou Infectious
Diseases Hospital Ethics Review Committee, First Affili-
ated Hospital of Wenzhou Medical University Ethics
Review Committee, First Affiliated Hospital of Third
Military Medical University Ethics Review Committee,
Guangzhou No 8 People’s Hospital Ethics Review Com-
mittee, Shanghai Public Health Clinical Center Ethics
Review Committee, Affiliated Hospital of Chengdu Uni-
versity of Traditional Chinese Medicine Ethics Review
Committee and Tianjin Second People’s Hospital Ethics
Review Committee.
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The randomized subjects who have taken at least one
dose of study drug and are evaluated for at least once
curative effect after taking medication, constitute the full
analysis set and safety analysis set. Those who complete
all the visits comprise the per-protocol set. The statis-
tical analysis will be performed using SAS 9.1 software
(SAS Institute, Cary, NC, USA). The overall loss rate
due to adverse events of each group will be calculated.
When subjects enter the trial, they are assessed for
demographic data, baseline condition and other essential
information and are compared between groups. Cumula-
tive incidence of HCC and overall survival rate will be
determined by Kaplan–Meier analysis, and the log-rank
test will be used for treatment comparisons. Changes
from baseline in liver histology (METAVIR score) as well
as in liver and spleen imaging (type B ultrasound)
between the two groups will be compared by the
Cochran–Mantel–Haenszel test. Changes from baseline
in serum markers for liver fibrosis and liver function,
transient electrograph (FibroScan) and TCM syndrome
between the two groups will be compared by a covari-
ance or non-parametric test. The statistical significance
is defined as a two-sided P <0.05.
Discussion
HBV is a common infection that is associated with a
considerable burden of liver-related morbidity and mor-
tality worldwide [28]. HBV is strongly associated with
HCC by its presence in tumor cells and by the role of
persistent HBV infection as a risk factor for the develop-
ment of HCC [29]. Recent advances have seen the intro-
duction of drug therapy with the potential to have a
significant impact on the incidence of liver-related
complications [28]. In particular, treatment of CHB has
dramatically improved over the past decade [30-32],
but persistent HBV infection is still the most common
underlying cause of HCC, which remains one of the
most common cancers worldwide [33]. Cirrhosis and
persistently high viremia are both important risk factors
for HCC in patients with CHB [4,33,34]. Therefore, anti-
viral therapy could theoretically prevent HCC by inhibit-
ing HBV replication and preventing the development of,
or even reversing, cirrhosis [30-32]. Antiviral therapy
alone does not remove this risk and occurrence of HCC
[7]. However, it has not been demonstrated whether a
combination of TCM and antiviral therapy could have a
role in preventing or delaying the development of HCC
in patients with CHB.
Clinical trials have been carried out to evaluate the
role and efficacy of RGT for HBV-related hepatic fibrosis
and compensated cirrhosis [10,15-18]. RGT administered
to block and reverse hepatic fibrosis in CHB or HBV-
related compensated cirrhosis is considered one of thetreatment options for patients with hepatic fibrosis. Only
limited data are available about the effects of RGT
blockade and reversal of hepatic fibrosis on the develop-
ment of HCC in patients with CHB. To date, there have
been no RCTs comparing the effects of combined appli-
cation of RGT and NUCs with NUCs alone on the devel-
opment of HCC in patients with CHB or HBV-related
compensated cirrhosis.
The present clinical trial introduces promising and
classical herbs and formulae into the treatment of
hepatitis-B-related hepatic fibrosis and compensated cir-
rhosis. Above all, this clinical study evaluates for patients
with CHB or HBV-related compensated cirrhosis: (1) the
efficacy of TCM (RGT) in preventing or delaying the oc-
currence of HCC, (2) the efficacy of RGT in reducing
the development of decompensated cirrhosis and disease
progression for patients with CHB or HBV-related com-
pensated cirrhosis and (3) whether TCM treatment im-
proves the hepatic microenvironment and reduces the
development of HCC.
In summary, the results of the present trial are of
value because they will provide an important evidence
base for the effects of TCM blockade and reversal of
hepatic fibrosis on development of HCC for patients
with CHB or HBV-related compensated cirrhosis.
Trial status
Patient recruitment for this trial is ongoing. Data collec-
tion will continue until the end of November 2018.
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